Expanded Access Programs (EAPs) provide patients much-needed access to promising investigational drugs, outside the clinical trial setting. They are typically set up during phase 2 or phase 3 studies, to supply patients that are ineligible or excluded from the clinical trial, or once phase 3 trials have ended, to provide continued treatment access until commercial product becomes available.
EAPs offer a variety of benefits to sponsor companies, and regulatory bodies around the world encourage the use of expanded access, where and when appropriate.
If your company is developing a drug that fulfils an unmet clinical need, you may have already started receiving patient enquiries about expanded access. Now is the time to consider if and how a program could work for your product.
WEP Clinical has put together this downloadable resource that lists the kinds of questions companies should be asking when considering or planning an EAP. Please complete the form below to download the resource.